Matches in SemOpenAlex for { <https://semopenalex.org/work/W2465561570> ?p ?o ?g. }
- W2465561570 endingPage "1174" @default.
- W2465561570 startingPage "1164" @default.
- W2465561570 abstract "BRAF inhibitors (BRAFi) have proven clinical benefits in patients with BRAF-mutant melanoma. However, acquired resistance eventually arises. The effects of BRAFi on melanoma cell proliferation and survival have been extensively studied, and several mechanisms involved in acquired resistance to the growth suppressive activity of these drugs have been identified. Much less is known about the impact of BRAFi, and in particular of dabrafenib, on the invasive potential of melanoma cells. In the present study, the BRAF-mutant human melanoma cell line A375 and its dabrafenib-resistant subline A375R were analyzed for invasive capacity, expression of vascular endothelial growth factor receptor (VEGFR)-2, and secretion of VEGF-A and matrix metalloproteinase (MMP)-9, under basal conditions or in response to dabrafenib. The consequences of inhibiting the PI3K/AKT/mTOR pathway on A375R cell responses to dabrafenib were also evaluated. We found that A375R cells were more invasive and secreted higher levels of VEGF-A and MMP-9 as compared with A375 cells. Dabrafenib reduced invasiveness, VEGFR-2 expression and VEGF-A secretion in A375 cells, whereas it increased invasiveness, VEGF-A and MMP-9 release in A375R cells. In these latter cells, the stimulating effects of dabrafenib on the invasive capacity were markedly impaired by the anti-VEGF‑A antibody bevacizumab, or by AKT1 silencing. A375R cells were not cross-resistant to the PI3K/mTOR inhibitor GSK2126458A. Moreover, this inhibitor given in combination with dabrafenib efficiently counteracted the stimulating effects of the BRAFi on invasiveness and VEGF-A and MMP-9 secretion. Our data demonstrate that melanoma cells with acquired resistance to dabrafenib possess a more invasive phenotype which is further stimulated by exposure to the drug. Substantial evidence indicates that continuing BRAFi therapy beyond progression produces a clinical benefit. Our results suggest that after the development of resistance, a regimen combining BRAFi with bevacizumab or with inhibitors of the PI3K/AKT/mTOR pathway might be more effective than BRAFi monotherapy." @default.
- W2465561570 created "2016-07-22" @default.
- W2465561570 creator A5003572747 @default.
- W2465561570 creator A5005666712 @default.
- W2465561570 creator A5014531698 @default.
- W2465561570 creator A5024644508 @default.
- W2465561570 creator A5027939174 @default.
- W2465561570 creator A5049053355 @default.
- W2465561570 creator A5049101338 @default.
- W2465561570 creator A5059770670 @default.
- W2465561570 creator A5085978275 @default.
- W2465561570 date "2016-06-30" @default.
- W2465561570 modified "2023-10-14" @default.
- W2465561570 title "Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor" @default.
- W2465561570 cites W1217284267 @default.
- W2465561570 cites W1502777599 @default.
- W2465561570 cites W1539571840 @default.
- W2465561570 cites W1570494660 @default.
- W2465561570 cites W1576116802 @default.
- W2465561570 cites W1943317391 @default.
- W2465561570 cites W1965370740 @default.
- W2465561570 cites W1970323663 @default.
- W2465561570 cites W1971078959 @default.
- W2465561570 cites W1972308715 @default.
- W2465561570 cites W1985821753 @default.
- W2465561570 cites W1989250261 @default.
- W2465561570 cites W2005334224 @default.
- W2465561570 cites W2007553857 @default.
- W2465561570 cites W2009081283 @default.
- W2465561570 cites W2025130458 @default.
- W2465561570 cites W2030537668 @default.
- W2465561570 cites W2030846098 @default.
- W2465561570 cites W2032099289 @default.
- W2465561570 cites W2038264590 @default.
- W2465561570 cites W2050904301 @default.
- W2465561570 cites W2050991236 @default.
- W2465561570 cites W2052781279 @default.
- W2465561570 cites W2058390096 @default.
- W2465561570 cites W2060938351 @default.
- W2465561570 cites W2065272192 @default.
- W2465561570 cites W2069195505 @default.
- W2465561570 cites W2070932010 @default.
- W2465561570 cites W2071525523 @default.
- W2465561570 cites W2080626878 @default.
- W2465561570 cites W2094953205 @default.
- W2465561570 cites W2100887597 @default.
- W2465561570 cites W2102585212 @default.
- W2465561570 cites W2103441770 @default.
- W2465561570 cites W2111381709 @default.
- W2465561570 cites W2119180969 @default.
- W2465561570 cites W2124073148 @default.
- W2465561570 cites W2128542677 @default.
- W2465561570 cites W2129349376 @default.
- W2465561570 cites W2136474966 @default.
- W2465561570 cites W2139707889 @default.
- W2465561570 cites W2142019721 @default.
- W2465561570 cites W2142913791 @default.
- W2465561570 cites W2143926802 @default.
- W2465561570 cites W2154196978 @default.
- W2465561570 cites W2155420645 @default.
- W2465561570 cites W2156078931 @default.
- W2465561570 cites W2160766792 @default.
- W2465561570 cites W2161018320 @default.
- W2465561570 cites W2163188200 @default.
- W2465561570 cites W2163655212 @default.
- W2465561570 cites W2166262263 @default.
- W2465561570 cites W2225287204 @default.
- W2465561570 cites W2334193406 @default.
- W2465561570 doi "https://doi.org/10.3892/ijo.2016.3594" @default.
- W2465561570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27572607" @default.
- W2465561570 hasPublicationYear "2016" @default.
- W2465561570 type Work @default.
- W2465561570 sameAs 2465561570 @default.
- W2465561570 citedByCount "46" @default.
- W2465561570 countsByYear W24655615702017 @default.
- W2465561570 countsByYear W24655615702018 @default.
- W2465561570 countsByYear W24655615702019 @default.
- W2465561570 countsByYear W24655615702020 @default.
- W2465561570 countsByYear W24655615702021 @default.
- W2465561570 countsByYear W24655615702022 @default.
- W2465561570 countsByYear W24655615702023 @default.
- W2465561570 crossrefType "journal-article" @default.
- W2465561570 hasAuthorship W2465561570A5003572747 @default.
- W2465561570 hasAuthorship W2465561570A5005666712 @default.
- W2465561570 hasAuthorship W2465561570A5014531698 @default.
- W2465561570 hasAuthorship W2465561570A5024644508 @default.
- W2465561570 hasAuthorship W2465561570A5027939174 @default.
- W2465561570 hasAuthorship W2465561570A5049053355 @default.
- W2465561570 hasAuthorship W2465561570A5049101338 @default.
- W2465561570 hasAuthorship W2465561570A5059770670 @default.
- W2465561570 hasAuthorship W2465561570A5085978275 @default.
- W2465561570 hasBestOaLocation W24655615701 @default.
- W2465561570 hasConcept C2776131300 @default.
- W2465561570 hasConcept C2777658100 @default.
- W2465561570 hasConcept C2778472372 @default.
- W2465561570 hasConcept C2778830669 @default.
- W2465561570 hasConcept C2994587330 @default.
- W2465561570 hasConcept C502942594 @default.